Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gale

Showing results (321-330 of 361) with videos related to

Pageof 37
Sort By:
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Protective <i>IFIH1</i> variant reduces immune-mediated islet stress and dysfunction in a type 1 diabetes genetic backgroundDaniel A Veronese-Paniagua, Cameron Banks, Kameron Bradley, et al.
Nature Cell Biology|May 15, 2023
Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specificationPunn Augsornworawat, Nathaniel J Hogrebe, Matthew Ishahak, et al.
Nature Cell Biology|August 9, 2023
Author Correction: Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specificationPunn Augsornworawat, Nathaniel J Hogrebe, Matthew Ishahak, et al.
Leukemia & Lymphoma|May 19, 2016
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208Adriana E Tron, Erika K Keeton, Minwei Ye, et al.
Journal of Critical Care|June 26, 2020
Effect of in-bed cycling on acute muscle wasting in critically ill adults: A randomised clinical trialMarc R Nickels, Leanne M Aitken, Adrian G Barnett, et al.
Blood|November 23, 2016
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLSteven Knapper, Nigel Russell, Amanda Gilkes, et al.
British Journal of Haematology|March 26, 2013
Does BCR/ABL1 positive acute myeloid leukaemia exist?Ellie P Nacheva, Colin D Grace, Diana Brazma, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
Blood|August 18, 2005
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaRosemary E Gale, Robert Hills, Arnold R Pizzey, et al.
Pageof 37

Showing results (321-330 of 361) with videos related to

Sort By:
Pageof 37
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Protective <i>IFIH1</i> variant reduces immune-mediated islet stress and dysfunction in a type 1 diabetes genetic backgroundDaniel A Veronese-Paniagua, Cameron Banks, Kameron Bradley, et al.
Nature Cell Biology|May 15, 2023
Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specificationPunn Augsornworawat, Nathaniel J Hogrebe, Matthew Ishahak, et al.
Nature Cell Biology|August 9, 2023
Author Correction: Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specificationPunn Augsornworawat, Nathaniel J Hogrebe, Matthew Ishahak, et al.
Leukemia & Lymphoma|May 19, 2016
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208Adriana E Tron, Erika K Keeton, Minwei Ye, et al.
Journal of Critical Care|June 26, 2020
Effect of in-bed cycling on acute muscle wasting in critically ill adults: A randomised clinical trialMarc R Nickels, Leanne M Aitken, Adrian G Barnett, et al.
Blood|November 23, 2016
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLSteven Knapper, Nigel Russell, Amanda Gilkes, et al.
British Journal of Haematology|March 26, 2013
Does BCR/ABL1 positive acute myeloid leukaemia exist?Ellie P Nacheva, Colin D Grace, Diana Brazma, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
Blood|August 18, 2005
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaRosemary E Gale, Robert Hills, Arnold R Pizzey, et al.
Pageof 37